Late Effects After Hematopoietic Stem Cell Transplantation Among Childhood Transplant Survivors with Fanconi AnemiaCansu Ozkocer1, Fatma Visal Okur2, Huseyin Demirbilek3, Burak Altintas1, Nevin Cetin2, Bulent Baris Kuskonmaz2, Bora Gulhan4, Hayrettin Hakan Aykan5, Hulya Demir6, Deniz Dogru Ersoz7, Ugur Canpolat8, Hasan Serkan Dogan9, Elmas Nazli Gonc3, Hatice Yasemin Yasemin Balaban4, Gurkan Bozdag5, Sule Unal2, Sevkiye Selin Aytac Eyupoglu2, Rezan Topaloglu4, Zeynep Alev Ozon3, Fatma Gumruk2, Duygu Uçkan Çetinkaya101Department of Pediatrics, Faculty of Medicine, Hacettepe University, Ankara, Turkey 2Division of Pediatric Hematology and Bone Marrow Transplantation Unit, Department of Pediatrics, Faculty of Medicine, Hacettepe University, Ankara, Turkey 3Division of Pediatric Endocrinology, Department of Pediatrics, Faculty of Medicine, Hacettepe University, Ankara, Turkey 4Division of Pediatric Nephrology, Department of Pediatrics, Faculty of Medicine, Hacettepe University, Ankara, Turkey 5Division of Pediatric Cardiology, Department of Pediatrics, Faculty of Medicine, Hacettepe University, Ankara, Turkey 6Division of Pediatric Gastroenterology, Department of Pediatrics, Faculty of Medicine, Hacettepe University, Ankara, Turkey 7Division of Pediatric Pulmonology, Department of Pediatrics, Faculty of Medicine, Hacettepe University, Ankara, Turkey 8Department of Cardiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey 9Department of Urology, Faculty of Medicine, Hacettepe University, Ankara, Turkey 10Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey
Objective: Background: Fanconi anemiais the most common inherited bone marrow failure syndrome. HSCT remains the only curative treatment for hematological manifestations of FA. Despite restoration of long-term hematopoiesis, patients continue to remain at risk of late effects. Objectives: In our study, we aimed to reveal the problems that occur in the long-term follow-up of FA patients, and point out an ongoing need for the improvement of long-term follow-up guidelines for childhood transplant survivors with FA. Materials and Methods: Study Design: In this single centered, cross-sectional study, we analyzed the long-term outcome of 36 patients with FA according to current recommendations with a median age of 18.1 years (range: 6.1-36 years, male/female, 24/12)who underwent a HSCT at Pediatric Bone Marrow Transplantation (BMT) Unit between 1995 and 2019 and survived at least one year post-transplant. Results: The median long-term follow-up time was 8 years (range, 1-25 years). Gonadal dysfunction was detected in about 35% of our patients. 31% of the patients had hypergonadotropic hypogonadism, 4 % had hypogonadotropic hypogonadism. When the patients were evaluated for growth impairment, 7 of 12 patients who reached their final adult height and 12 of 21 patients who didn’t complete their growth, had height standard deviation score below –2 SD. Three patients (9%) developed subclinical hypothyroidism, two (6%) had overt hypothyroidism and one (3%) had central hypothyroidism. Although, none of our patients fully met the criteria for metabolic syndrome, 23% of the patients had insulin resistance and 39% had dyslipidemia. Evaluation of organ dysfunctions revealed that almost 50% of the patients had obstructive and 21 % had restrictive changes in their pulmonary function tests. Hepatosteatosis was detected in 15% of the patients and mild valve dysfunction was detected in 50 % of evaluable patients. Three patients developed secondary malignancies. Squamous cell cancer developed in 2 patients and basal cell cancer in one patient. Conclusion: A risk-defined multidisciplinary approach for long-term follow up of children with FA undergoing HSCT is essential for early detection and management of late effects.
Keywords: Fanconi anemia, hematopoietic stem cell transplantation, late effects, children, long-term follow-up
Corresponding Author: Cansu Ozkocer
|
|